Abstract
Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
Keywords: Biologics, dermatomyositis, interstitial lung disease, polymyositis.
Current Pharmaceutical Biotechnology
Title:Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease
Volume: 15 Issue: 6
Author(s): Yuechi Sun, Yan He, Yuan Liu and Guixiu Shi
Affiliation:
Keywords: Biologics, dermatomyositis, interstitial lung disease, polymyositis.
Abstract: Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
Export Options
About this article
Cite this article as:
Sun Yuechi, He Yan, Liu Yuan and Shi Guixiu, Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910145940
DOI https://dx.doi.org/10.2174/138920101506140910145940 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
Cardiovascular & Hematological Disorders-Drug Targets BCR/ABL1 Fusion Transcripts Generated from Alternative Splicing: Implications for Future Targeted Therapies in Ph+ Leukaemias
Current Molecular Medicine Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry The Enzymology of Cytosolic Pyrimidine 5’-Nucleotidases: Functional Analysis and Physiopathological Implications.
Current Medicinal Chemistry Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
Current Topics in Medicinal Chemistry Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry PET Designated Flouride-18 Production and Chemistry
Current Topics in Medicinal Chemistry Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Glycomics: Towards Bioinformatic Approaches to Understanding Glycosylation
Anti-Cancer Agents in Medicinal Chemistry A Systematic Review of the Molecular Mechanisms of Uranium -Induced Reproductive Toxicity
Inflammation & Allergy - Drug Targets (Discontinued) Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets